profit from every $100 of sales.
$0$100
GoodRx Holdings
$3.56+1.42% today
+16.0% in 1 year
1-year low $1.871-year high $3.80
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $39.90 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What GoodRx Holdings sold, what it kept, and what it did with the cash.
Sales went from $767 million in 2022 to $797 million in 2025, with $30.4 million of profit last year.
SalesProfit
GoodRx Holdings handed back more cash to shareholders than it generated last year.
Buybacks $216M
Free cash flow 2025$94M
Bought back its own shares$216M
Paid as dividends–
Cash vs. debt$262M vs. $543M
GoodRx Holdings vs. similar companies
GoodRx Holdings grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| GoodRx Holdings | 39.9× · Expensive | ||
 GE HealthCare Technologies | 18.0× · Fair price | ||
 BrightSpring Health Services | 74.3× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.8× · Expensive |
AI analysis
An AI analyst reads GoodRx Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 767 | 750 | 792 | 797 | |
| 701 | 683 | 744 | 739 | |
| 2 | -27 | 66 | 87 | |
| 65 | 109 | 154 | 184 | |
| -33 | -9 | 16 | 30 | |
| -0.08 | -0.02 | 0.04 | 0.09 | |
| 91.5% | 91.1% | 93.9% | 92.8% | |
| 0.2% | -3.6% | 8.3% | 11.0% | |
| -4.3% | -1.2% | 2.1% | 3.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,605 | 1,589 | 1,388 | 1,404 |
| Cash | 757 | 672 | 448 | 262 |
| Total debt | 717 | 711 | 543 | 543 |
| Total liabilities | 790 | 827 | 663 | 788 |
| 815 | 762 | 725 | 616 | |
| 413 | 410 | 392 | 357 | |
| 0.6% | 0.1% | 5.3% | 6.8% | |
| -4.0% | -1.2% | 2.3% | 4.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 147 | 138 | 184 | 168 | |
| 55 | 56 | 70 | 74 | |
| 92 | 83 | 114 | 94 | |
| Dividends paid | – | – | – | – |
| 102 | 104 | 159 | 216 | |
| 120 | 105 | 99 | 77 |
Valuation
- 39.9×
- 11.3×
- –
- 1.5×
- 1.5×
- 12.9×
- 8.1×
- 7.7%
- 2.5%
- 0.0%
Profitability
- 92.8%
- 11.0%
- 3.8%
- 22.2%
- 4.7%
- 0.3%
- 4.8%
- 1.5%
- 7.3%
- 15.2%
Growth
- +1.3%
- –
- +44.8%
- –
- −3.4%
Financial health
- 1.5×
- 0.09
- 2.9%
- 2.1×
- 1.47
- 1.47
- 0.39
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 45%of 952
Top 46%of 883
Bottom 30%of 601
Bottom 20%of 888
Top 12%of 987
What analysts expect
- Average price target
- $3.19
- Range
- $2.75 – $4.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.07 | 0.07 | +0.0% |
| Feb 25, 2026 | 0.09 | 0.09 | +0.0% |
| Nov 4, 2025 | 0.08 | 0.09 | −11.1% |
| Aug 6, 2025 | 0.09 | 0.10 | −10.0% |
| May 7, 2025 | 0.09 | 0.09 | +0.0% |
| Feb 27, 2025 | 0.09 | 0.10 | −10.0% |
| Nov 7, 2024 | 0.08 | 0.09 | −11.1% |
| Aug 8, 2024 | 0.08 | 0.09 | −11.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
39No pass
Philip Fisher
44No pass
Peter Lynch
42No pass
Joel Greenblatt
29No pass
Charlie Munger
43No pass
Terry Smith
33No pass
Questions about GoodRx Holdings
Is GoodRx Holdings a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the GoodRx Holdings AI analysis
What does GoodRx Holdings do?
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. It is in Medical - Healthcare Information Services.
Does GoodRx Holdings pay a dividend?
No. GoodRx Holdings does not pay a dividend at the moment; in 2025 it returned $216 million to shareholders by buying back its own shares.
Is GoodRx Holdings stock halal?
No. GoodRx Holdings does not pass our halal screen: its debt is 45% of its market value, at or above the 33% limit. How we check
How has GoodRx Holdings stock done over the past year?
Up 16.0% over the past twelve months, to $3.56. It traded between $1.87 and $3.80 and is 6.3% below its high.
Who are GoodRx Holdings's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with GoodRx Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.